Form PTO-1449 (modified)	Atty. Docket No. UTSG:239/SHS	Serial No. 09/418,095
List f Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant John A. Copland, III, Slavisa Gasic, Randall J. Urban, Melvyn Soloff	
	Filing Date: October 14, 1999	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
QN	A1	4,690,915	9/1/87	Rosenberg	514	2	8/8/85
↓	A2	5,199,942	4/6/93	Gillis	604	4	9/26/91
↓	A3	5,478,852	12/26/95	Olefsky *et al.*	514	369	8/23/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C1	Auersperg *et al.*, "Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes," *Lab. Invest.* 71:510-518, 1994.
↓	C2	Auersperg *et al.*, "Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer," *Am. J. Obstetr. Gynecol.*, 173:558-565, 1995.
↓	C3	Bao *et al.*, "Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas," *Hum. Gene Ther.*, 7:355-365, 1996.
↓	C4	Bass *et al.*, "Recombinant adenovirus-mediated gene transfer to genitourinary epithelium *in vitro* and *in vivo*," *Cancer Gene Ther.*, 2:97-104, 1995.
↓	C5	Chinery *et al.*, Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 $^{WAF1/CIP1}$," *Nature Medicine* 3:1233-1241, 1997.
↓	C6	Culver *et al.*, "In Vivo Gene Transfer with retroviral vector-producer cells for treatment of experimental brain tumors," *Science*, 256:1550-1552, 1992.
↓	C7	Dong *et al.*, "Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector," *Hum. Gene Ther.*, 7:319-331, 1996.

EXAMINER: Quang Nguyen | **DATE CONSIDERED:** 08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSG:239/SHS	Serial No. 09/418,095
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: John A. Copland, III, Slavisa Gasic, Randall J. Urban, Melvyn Soloff	
	Filing Date: October 14, 1999	Gr up: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C8	Dyck *et al.*, "Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer," *Int J Cancer* 69:429-436, 1996.
	C9	Elstner *et al.*, "Ligands for peroxisome prliferator-activated receptor ϒ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells *in vitro* and in BNX mice, *Proc. Natl. Acad. Sci. USA*, 95:8806-8811, 1998.
	C10	Jacobs *et al.*, "Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and x-chromosome inactivation," *J Natl Cancer Inst.*, 84:1793-1798, 1992.
	C11	Jiang *et al.*, "PPARϒ agonists inhibit production of monocyte inflammatory cytokines," *Nature*, 391:82-86,1998.
	C12	Kliewer and Wilson, "The nuclear receptor PPARϒ - bigger than fat," *Curr. Opin. Genet. Dev.*, 8:576-581, 1998.
	C13	Kliewer *et al.*, "Convergence of 9-cis retinoic acid and peroxisome proliferator signallin pathways through heterodimer formation of their receptors," Nature 358:771-774, 1992.
	C14	Kliewer *et al.*, "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," *Proc. Natl Acad. Sci. USA*, 91:7355-7359, 1994.
	C15	Kubota *et al.*, "Ligand for peroxisome proliferator-activated receptor ϒ (troglitazone) has potent antitumor effect against human prostate cancer both *in vitro* and *in vivo*," *Cancer Res* 58:3344-3352, 1998.
	C16	Lefebvre *et al.*, "Activation of the peroxisome proliferator-activated receptor ϒ promotes the development of colon tumors in C57BL/6J-APC^{min}/+ mice," *Nature Medicine*, 4: 1053-1057, 1998.
	C17	Lehmann *et al.*, "Peroxisome proliferator-activated receptors αand ϒ are activated by indomethacin and other non-steroidal anti-inflammatory drugs," *J. Biological Chem.*, 272:3406-3410, 1997.
	C18	Mok *et al.*, "DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer," *Oncogene* 16:2381-2387, 1998.
✓	C19	Mok *et al.*, "Unifocal origin of advanced human epithelial ovarian cancers," *Cancer Res* 52:5119-5122. 1993.

EXAMINER: Quang Nguyen **DATE CONSIDERED:** 08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSG:239/SHS	Serial N . 09/418,095
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant John A. Copland, III, Slavisa Gasic, Randall J. Urban, Melvyn Soloff	
	Filing Date: October 14, 1999	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C20	Mueller *et al.*, "Terminal differentiation of human breast cancer through PPARΥ," *Molecular Cell* 1:465-470, 1998.
	C21	Warrel *et al.*, "Acute promyelocytic leukemia," *N Engl. J Med* 329:177-189, 1993.
	C22	Qazi and McGuire, "The treatment of epithelial ovarian cancer," *CA Cancer J Clin* 45:88-101, 1995.
	C23	Yu *et al.*, "Differential activation of peroxisome proliferator-activated receptors by eicosanoids," *J. Bio. Chem.*, 270:23975-23983, 1995.
	C24	Ricote *et al.*, "The peroxisome proliferator-activated receptor-Υ is a negative regulator of macrophage activation," *Nature*, 391:79-85, 1998.
	C25	Rubinstein *et al.*, "Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines," *J. Natl. Cancer Inst.*, 82:1113-1120, 1990.
	C26	Saltiel and Olefsky, "Thiazolidinediones in the treatment of insulin resistance and type II diabetes," *Diabetes*, 45:1661-1669, 1996.
	C27	Sarraf *et al.*, "Differentiation and reversal of malignant changes in colon cancer through PPARΥ," *Nature Medicine* 4:1046-1052, 1998.
	C28	Sears *et al.*, "Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor Υ," *Mol. Cell Biol.* 16:3410-3418, 1996.
	C29	Sherr, "Cancer Cell Cycles," *Science*, 274:1672-1677, 1996.
	C30	Stauble *et al.*, "Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and d-α-tocopherol in vascular smooth muscle cells," *Eur. J. Biochem.*, 226:393-402, 1994.
	C31	Steiner *et al.*, "DI-alpha-tocopherol, a potent inhibitor of phorbol ester induced shape change of erythro- and megakaryoblastic leukemia cells," *J. Cellular Physiology*, 172:351-360, 1997.
W	C32	Sugimura *et al.*, "Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor," *Biochemical and Biophysical Res. Communications*, 261:833-837, 1999.

EXAMINER: Quang Nguyen	DATE CONSIDERED: 08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSG:239/SHS	Serial No. 09/418,095
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant John A. Copland, III, Slavisa Gasic, Randall J. Urban, Melvyn Soloff	
	Filing Date: October 14, 1999	Group: 1646

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C33	Tontonoz *et al.*, "mPPARγ2: tissue-specific regulator of an adipocyte enhancer," *Nucleic Acids Res* 22:5628-5634, 1994.
	C34	Tontonoz *et al.*, " Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα," *Genes Dev* 8:1224-1234, 1994.
	C35	Tontonoz *et al.*, "PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene," *Mol. Cell Biol.* 15:351-357, 1995.
	C36	Tontonoz *et al.*, "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid x receptor," *Proc Natl Acad Sci USA* 94:237-241, 1997.
	C37	Tsao *et al.*, "Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas,"*Gynecol Oncology* 48:5-10, 1993.
	C38	Turley *et al.*, "Vitamin E succinate inhibits proliferation of bt-20 human breast cancer cells: increase binding of cyclin A negatively regulates E2F transactivation activity," *Cancer Research*, 57:2668-2675, 1997.

EXAMINER: Quang Nguyen | **DATE CONSIDERED:** 08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.